- Home
- ANTX vs NERV Comparison
ANTX vs NERV Comparison
Compare ANTX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | NERV |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 29.2M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTX | NERV |
|---|---|---|
| Price | $1.31 | $4.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 107.1K | 55.2K |
| Earning Date | 11-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.15 |
| 52 Week High | $1.55 | $12.46 |
Technical Indicators
Market Signals| Indicator | ANTX | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 66.18 |
| Support Level | $1.00 | $3.82 |
| Resistance Level | $1.35 | $4.86 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 90.60 | 84.62 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.